购物车
- 全部删除
- 您的购物车当前为空
Cytochalasin B is a mycotoxin binding to the barbed end of actin filaments. It can disrupt the formation of actin polymers (Kd: 1.4-2.2 nM for F-actin).
Cytochalasin B is a mycotoxin binding to the barbed end of actin filaments. It can disrupt the formation of actin polymers (Kd: 1.4-2.2 nM for F-actin).
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 787 | 5日内发货 |
产品描述 | Cytochalasin B is a mycotoxin binding to the barbed end of actin filaments. It can disrupt the formation of actin polymers (Kd: 1.4-2.2 nM for F-actin). |
靶点活性 | F-actin (Mg2+/K+):1.4 nM (Kd), F-actin (Mg2+):2.2 nM (Kd) |
体外活性 | Cytochalasin B is a cell-permeable mycotoxin binding to the barbed end of actin filaments, inhibits the enlongation and shortening of actin filaments, with Kds of 2.2 nM and 1.4 nM for F-actin in the presence of MgCl2 (2 mM) or MgCl2 (2 mM) plus KCl, respectively [1]. Cytochalasin B (6 μM) increases the myofibrillar fragmentation index, which is attributed to the intensely breaking of myofibrillar proteins into short segments. Cytochalasin B also accelerates the disruption of actin filaments. In addition, Cytochalasin B accelerates the transformation from F-actin to G-actin, lowering the content of F-actin and significantly increasing G-actin bands during postmortem conditioning [2]. Cytochalasin B (0.1-10 μM) shows inhibitory effect on multiple murine cancer cell lines, with IC50s of 2.56 μM (M109c), 10.46 μM (B16BL6), 105.5 μM (P388/ADR), 51.9 μM (P388/S) and IC80s of 12.23 μM (M109c), 44.86 μM (B16BL6), 188.4 μM (P388/ADR), 84.1 μM (P388/S) after treatment for 3 h, with IC50s of 0.25 μM (M109c), 0.37 μM (B16F10), 0.87 μM (B16BL6), and IC80s of 0.75 μM (M109c), 1.21 μM (B16F10) after treatment for 4 days [3]. |
体内活性 | Cytochalasin B (10, 25, 50 mg/kg, i.p.) dose-dependently increases the life expectancy of Balb/c mice bearing with P388/ADR leukemias. Cytochalasin B at 50 mg/kg produces 10 % long-term survival in the multidrug-resistant P388/ADR cohort, and 40 % long-term survival in the drug-sensitive P388/S cohort [3]. |
细胞实验 | The attached cell lines M109c, B16BL6, and B16F10 are seeded at 1 to 4?×?10^4 cells/mL in 2 mL volumes in 24-well culture plates 1 day prior to treatment with Cytochalasin B. The suspension culture of P388/ADR cells is seeded at 5?×?10^4 cells/mL and allowed to grow overnight before Cytochalasin B treatment. Cells are treated with Cytochalasin B for 3 h, as well as 2, 3, or 4 days. In the case of continuous exposure for 2, 3, or 4 days, attached cells are trypsinized and counted with a hemacytometer. Leukemia cell suspensions are counted with a Coulter Counter. In the case of short-term exposure, cells are washed twice with fresh medium, then trypsinized (except for P388/ADR cells), reseeded, and allowed to regrow for 3 days, at which time they are counted. Growth results are calculated as the number of cells generated above the seeding density compared to the untreated control cells and graphically presented as a percent of control increase [3]. |
动物实验 | For chemotherapy testing, Balb/c mice under isoflurane anesthesia are challenged with 2?×?10^5 trypan blue negative P388/S or P388/ADR cells subcutaneously (s.c.) in a volume of 200 μL. Untreated mice are kept in order to determine the lethality of the challenge without chemotherapeutic intervention. Long-term survival is defined as challenged mice that survive the duration of the observation period. Cytochalasins B and D are prepared in suspension form in 2 % carboxymethyl cellulose 1 % tween 20 (CMC/Tw) for intraperitoneal (i.p.) administration. The congeners or the vehicle are administered to leukemia-challenged mice on Days 1-8 following the initial challenge [2]. |
别名 | 细胞松弛素B, 细胞松弛素 B, Phomin |
分子量 | 479.61 |
分子式 | C29H37NO5 |
CAS No. | 14930-96-2 |
Smiles | [H][C@]12[C@H](Cc3ccccc3)NC(=O)C11OC(=O)\C=C\[C@H](O)CCC[C@@H](C)C\C=C\[C@@]1([H])[C@H](O)C(=C)[C@H]2C |
密度 | 1.2 g/cm3 |
存储 | store at low temperature,keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||
溶解度信息 | Ethanol: 20 mg/mL (41.7 mM) DMSO: 20 mg/mL (41.7 mM) | |||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||
|
中药材名称 | 中药材拉丁名 | 性 | 味 | 归经 |
---|---|---|---|---|
土木香 | Inula helenium L. | 温 | 辛, 苦 | 肝, 脾 |
中成药名称 | 处方组成 | 中成药类型 |
---|---|---|
达斯玛保丸 | 铁棒锤,紫草茸,藏茜草,棘豆,多剌绿绒蒿,兔耳草,翼首草,诃子,金腰草,木香,土木香,唐古特乌头,止泻木子,安息香,人工麝香 | 清热药 |
二十一味寒水石散 | 寒水石(奶制),石榴子,甘青青兰,渣驯膏,余甘子,诃子(去核),唐古特乌头,绿绒蒿,土木香,小伞虎耳草,豆蔻,牛黄 | 祛瘀药 |
沉香安神胶囊 | 沉香,紫檀香,红花,豆蔻,诃子,旋复花,细辛,制草乌,木棉花,胡黄连,黑云香,枫香脂,山沉香,檀香,石膏,肉豆蔻,草果,栀子,白头翁,瞿麦,石榴,北沙参,丁香,木香,紫花地丁,苦参,川楝子,悬钩子木,山柰,广枣,兔心,土木香,麝香,降香,马钱子(制) | 清热药 |
纯阳正气胶囊 | 广藿香,半夏(制),土木香,陈皮,丁香,肉桂,苍术,白术,茯苓,朱砂,硝石(精制),硼砂,雄黄,金礞石(煅),人工麝香,冰片 | 温里药 |
调元大补二十五味汤散 | 红花,诃子,川楝子,栀子,土木香,川木香,苦地丁,胡黄连,秦艽,麦冬,石榴,酸梨干,贯众,小秦艽花,野菊花,细辛,芫荽果,木鳖子(制),猪血粉,款冬花,蓝盆花,瞿麦,香青兰,五灵脂,白豆蔻 | 扶正药 |
参芪健胃颗粒 | 党参,黄芪,白术,当归,白芍,茯苓,蒲公英,山楂,紫苏梗,土木香,桂枝,陈皮 | 扶正药 |
保心包 | 苏合香,川芎,丹参,三七,冰片,菊花,葛根,安息香,檀香,丁香,土木香,当归,郁金,沉香,黄芪,赤芍,香附,白芷,薤白,延胡索,决明子,降香,首乌藤,石菖蒲,乳香,没药 | 祛瘀药 |
肝康宁片 | 白花蛇舌草,垂盆草,虎杖,五味子,柴胡,人参,白术,丹参,郁金,三七,土木香,甘草 | 清热药 |
催汤丸 | 土木香,悬钩子茎(去皮,心),宽筋藤(去皮),干姜,诃子(去核),余甘子,毛诃子(去核),螃蟹甲 | 解表药 |
冠心苏合丸 | 苏合香,冰片,乳香(制),檀香,土木香 | 祛瘀药 |
苍苓止泻口服液 | 苍术,茯苓,金银花,柴胡,葛根,黄芩,马鞭草,金樱子,土木香,槟榔,甘草 | 清热药 |
沉香安神散 | 沉香,紫檀香,红花,白豆蔻,诃子,旋复花,细辛,制草乌,木棉花,胡黄连,黑云香,枫香脂,山沉香,檀香,石膏,肉豆蔻,草果,栀子,白头翁,瞿麦,石榴,北沙参,丁香,木香,紫花地丁,苦参,川楝子,悬钩子木,山柰,广枣,兔心,土木香,人工麝香,降香,马钱子(制) | 清热药 |
哈日十二味散 | 黑冰片,土木香,苦地丁,胡黄连,诃子,川楝子,栀子,人工牛黄,牛胆粉,石膏,红花,甘松 | 清热药 |
二十五味绿绒蒿胶囊 | 绿绒蒿,天竺黄,丁香,肉桂,木香,土木香,沉香,葡萄,渣驯膏,代赭石,红花,西红花,熊胆粉,人工麝香,小伞虎耳草,巴夏嘎,波棱瓜子,香附,荜茇,余甘子,干姜,甘草,甘青青兰,寒水石,人工牛黄,诃子 | 清热药 |
冠心苏合软胶囊 | 苏合香,冰片,乳香,檀香,土木香 | 祛瘀药 |
二十五味肺病胶囊 | 檀香,悬构木,石灰华,山柰,红花,葡萄,印度獐牙菜,甘草,兔耳草,沙棘膏,巴夏嘎,香旱芹,榜嘎,白花龙胆,诃子,肉果草,毛诃子,无茎芥,余甘子,甘肃蚤缀,土木香,铁棒锤(根,叶),宽筋藤,牛黄,力嘎都 | 清热药 |
保利尔胶囊 | 广枣,丹参,肉豆蔻,栀子,川楝子,茜草,红花,麦冬,三七,土木香,木香,檀香,人工牛黄,牛心,降香,大黄,木通,黄芪,荜茇,人工麝香,诃子 | 祛瘀药 |
冠心苏合咀嚼片 | 苏合香,冰片,乳香,檀香,土木香 | 祛瘀药 |
参梅养胃颗粒 | 北沙参,山楂,乌梅,红花,莪术,土木香,蒲公英,丹参,甘草,白芍,当归 | 扶正药 |
给喜古纳丸 | 大黄,土木香,干姜,诃子,寒水石(制),沙棘,碱花,白硇砂,方海,赤爮子,乌梢蛇 | 扶正药 |
方剂名称 | 处方组成 | 剂型 | 处方来源 |
---|---|---|---|
七圣紫金锭 | 土木香,苦花子,仙人薯,蚕沙,柏花,朱砂,雄黄 | 锭剂 | 《准绳·疡医》卷二。 |
消肿散5 | 蛇头抓,天藤,木虱药,仙人鲁,土木香,紫荆皮,大小青 | 散剂 | 《准绳·疡医》卷三。 |
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容